WO2025167738 - USE OF COMPOUND IN PREPARING MEDICAMENT FOR TREATING ANEMIA IN NON-MYELOID MALIGNANT TUMOR PATIENT

National phase entry is expected:
Publication Number WO/2025/167738
Publication Date 14.08.2025
International Application No. PCT/CN2025/074692
International Filing Date 24.01.2025
Title **
[English] USE OF COMPOUND IN PREPARING MEDICAMENT FOR TREATING ANEMIA IN NON-MYELOID MALIGNANT TUMOR PATIENT
[French] UTILISATION D'UN COMPOSÉ DANS LA PRÉPARATION D'UN MÉDICAMENT POUR LE TRAITEMENT DE L'ANÉMIE CHEZ UN PATIENT ATTEINT D'UNE TUMEUR MALIGNE NON MYÉLOÏDE
[Chinese] 化合物在制备治疗非髓系恶性肿瘤患者的贫血药物中的应用
Applicants **
SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD
Inventors
XIAO, Ying
MU, Shengmei
DUAN, Zhenfang
CHEN, Yuanyuan
XING, Yan
LIU, Zichen
LIN, Wei
Priority Data
202410169767.0   05.02.2024   CN
202410553582.X   07.05.2024   CN
Application details
Total Number of Claims/PCT *
Number of Independent Claims *
Number of Priorities *
Number of Multi-Dependent Claims *
Number of Drawings *
Pages for Publication *
Number of Pages with Drawings *
Pages of Specification *
*
Number of Office Actions *
*
International Searching Authority
*
Recordal of a Change of the Applicant's Name/Address
*
Type of Assignment
*
Applicant's Legal Status
*
*
*
*
*
*
Entry into National Phase under
*
Patent Delivery
*
Translation

* The data is based on automatic recognition. Please verify and amend if necessary.

** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.

Quotation for National Phase entry

Country StagesTotal
China Filing, Examination, Granting1632
EPO Filing, Examination, Granting11551
Japan Filing, Examination, Granting1907
South Korea Filing, Examination, Granting1636
USA Filing, Examination, Granting4740
MasterCard Visa
Total: 21,466
Contact Us
Abstract[English] Provided is use of a compound and a pharmaceutical composition thereof in preparing a medicament for treating anemia in a non-myeloid malignant tumor patient receiving chemotherapy, wherein the compound is N-[7-hydroxy-5-(2-phenylethyl)[1,2,4]triazole[1,5-a]pyridine-8-carbonyl]glycine.[French] L'invention concerne l'utilisation d'un composé et d'une composition pharmaceutique de celui-ci dans la préparation d'un médicament pour le traitement de l'anémie chez un patient atteint d'une tumeur maligne non myéloïde recevant une chimiothérapie, le composé étant la N-[7-hydroxy-5-(2-phényléthyl)[1,2,4]triazol[1,5-a]pyridine-8-carbonyl]glycine.[Chinese] 化合物及其药物组合物在制备用于治疗化疗的非髓系恶性肿瘤患者的贫血药物中的应用,其中,所述化合物是N-[7-羟基-5-(2-苯乙基)[1,2,4]三唑[1,5-a]吡啶-8-羰基]甘氨酸。